"Bevacizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-VEGF recombinant monoclonal antibody consisting of humanized murine antibody. It inhibits VEGF RECEPTORS and helps prevent the proliferation of blood vessels.
| Descriptor ID |
D000068258
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.375 D12.776.124.790.651.114.224.060.438 D12.776.377.715.548.114.224.200.438
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bevacizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Bevacizumab [D12.776.124.486.485.114.224.060.375]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Bevacizumab [D12.776.124.790.651.114.224.060.438]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Bevacizumab [D12.776.377.715.548.114.224.200.438]
Below are MeSH descriptors whose meaning is more specific than "Bevacizumab".
This graph shows the total number of publications written about "Bevacizumab" by people in this website by year, and whether "Bevacizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 6 | 6 |
| 2008 | 0 | 9 | 9 |
| 2009 | 0 | 7 | 7 |
| 2010 | 0 | 18 | 18 |
| 2011 | 0 | 16 | 16 |
| 2012 | 0 | 21 | 21 |
| 2013 | 0 | 12 | 12 |
| 2014 | 0 | 13 | 13 |
| 2015 | 1 | 4 | 5 |
| 2016 | 5 | 4 | 9 |
| 2017 | 3 | 2 | 5 |
| 2018 | 2 | 5 | 7 |
| 2019 | 8 | 4 | 12 |
| 2020 | 2 | 6 | 8 |
| 2021 | 2 | 8 | 10 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 5 | 5 |
| 2024 | 3 | 4 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bevacizumab" by people in Profiles.
-
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction. JAMA Oncol. 2024 Sep 01; 10(9):1253-1258.
-
Bevacizumab for Retinopathy of Prematurity Is Not Associated With Systemic Hypertension. J Pediatr Ophthalmol Strabismus. 2024 Nov-Dec; 61(6):434-441.
-
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
-
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment. Hepatology. 2025 Mar 01; 81(3):837-852.
-
Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future. Hepatol Commun. 2024 06 01; 8(6).
-
The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study. Gynecol Oncol. 2024 07; 186:17-25.
-
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). Pharmacogenomics J. 2024 Mar 04; 24(2):6.
-
Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta-analysis. Cancer Med. 2023 12; 12(24):21579-21591.
-
Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues? Eur J Cancer. 2023 11; 194:113349.
-
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2023 11 01; 30(11).